Please login to the form below

Not currently logged in
Email:
Password:

Phytopharm

This page shows the latest Phytopharm news and features for those working in and with pharma, biotech and healthcare.

Phytopharm shares dive as Parkinson's drug fails

Phytopharm shares dive as Parkinson's drug fails

Phytopharm shares dive as Parkinson's drug fails. Stock falls 80 per cent after Cogane failure in phase II. ... The latest disappointment comes after Phytopharm switched its initial focus on complex plant extract-derived pharmaceuticals.

Latest news

  • Still afloat

    Some cash-strapped but entrepreneurial examples include Cambridgeshire-based Phytopharm, whose novel molecule for Parkinson's and Alzheimer's has reversed the loss of dopaminergic neurones (restoring learning and memory ability)

  • Pharma news in brief

    Cash blow for Phytopharm. Phytopharm, which specialises in developing medicines from plants, reassured investors that finances were still strong, following the abrupt end to a £24m fund raising deal. ... However, Richard Dixey, Phytopharm's chief

  • Pharma news in brief

    Plant product firm reaches milestone. Biotech company Phytopharm, which specialises in generating medical products from plant extracts, has achieved its first interim profit as milestone payments from licensing partners rolled in. ... Phytopharm was also

  • R&D news in brief

    Phytopharm plans fundraising. Biopharmaceutical company Phytopharm, is planning to raise £23.9m through a UK placing, US private placing and open offer of 13.3m new shares. ... Phytopharm secured a licensing deal with Unilever in December 2004 for the

  • Pharma news in brief

    Phytopharm seeks bargaining funds. Phytopharm, a pharmaceutical plant-product research company, is seeking to raise £23.9m to strengthen its negotiating position with licensing partners.

More from news
Approximately 1 fully matching, plus 24 partially matching documents found.

Latest Intelligence

  • Pharma deals during February 2013 Pharma deals during February 2013

    Another failure this month has been Phytopharm's phase II compound, Cogane, in early stage Parkinson's disease. ... As Phytopharm does not have a portfolio of other late stage projects to develop in place of Cogane, the company is looking at “ other

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Novasecta

We are a specialist strategy consulting firm for pharmaceutical and biotech companies. We help our clients to achieve significant performance...

Latest intelligence

What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...
Marketing to healthcare professionals – what’s the key ingredient missing from most campaigns?
What do you think is the difference between a campaign developed to win a share-of-mind with consumers and a campaign designed to gain the attention of healthcare professionals?...

Infographics